References
- Brentjen R, Saltz L. Epidermal growth factor receptor blockade and treatment of solid tumor malignancies. De Vita JVT, Helmann S, Rosenberg SA, Progress in oncology. Boston, MA: Jones and Bartlett; 2002. 113–28.
- Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, . Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337–45.
- Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au H, . Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040–8.
- Pfeiffer P, Nielsen D, Yilmaz M, Iversen A, Vejlø C, Jensen BV. Cetuximab and irinotecan as third line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Acta Oncol 2007;46:697–701.
- Pfeiffer P, Nielsen D, Bjerregaard J, Qvortrup C, Yilmaz M, Jensen B. Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil. Ann Oncol 2008;19:1141–5.
- Tabernero J, Pfeiffer P, Cervantes A. Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: An effective, more convenient alternative to weekly administration? Oncologist 2008;13:113–9.
- Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, . Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658–64.
- Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004;25:581–611.
- Saltz LB, Lenz HJ, Kindler HL, Hochster HS, Wadler S, Hoff PM, . Randomized Phase II Trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: The BOND-2 Study. J Clin Oncol 2007;25:4557–61.
- Halama N, Herrmann C, Jaeger D, Hermann T. Treatment with cetuximab, bevacizumab and irinotecan in heavily pretreated patients with metastasized colorectal cancer. Anticancer Res 2008;28:4111–6.
- Tol J, Koopman CJ, Cats A, Cats A, Creemers GJ, Schrama JG, . A randomized phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity. Ann Oncol 2008;19:734–8.
- Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, . A randomized phase IIIB trial of chemotherapy, bevacizumab and panitumumab compared with chemotherapy and bevacizumab alone for metastasis colorectal cancer. J Clin Oncol 2009;5:672–80.
- Amado RG, Wolf M, Peeters M, Cutsem E, Siena S, Freeman DJ, . Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626–34.
- Karapetis CS, Khambata-Ford S, Jonker D, O´Callagan CJ, Tu D, Tebbutt NC, . K-RAS mutations and benefit from Cetuximab in advanced colorectal cancer. New Engl J Med 2008;359:1757–65.